Paclitaxel as a radiosensitiser: A proposed schedule of administration based on in vitro data and pharmacokinetic calculations

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 486-492

  Zanelli, G D ^a   Quaia, M ^a   Robieux, I ^a   Bujor, L ^a   Santarosa, M ^a   Favaro, D ^a   Spada, A ^a   Caffau, C ^a   Gobitti, C ^a   Trovo M G ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

cytotoxicity; paclitaxel; pharmacokinetics; radiosensitisation

Indexed keywords

CISPLATIN; PACLITAXEL; RADIOSENSITIZING AGENT;

ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; MELANOMA; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; X RAY;

EID: 0031105437     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89026-0     Document Type: Article

References (30)

1. Huizing MT, Sewberath Misser VH, et al. Taxanes: a new class of antitumor agents. Cancer Invest. 13:1995;381-404.
2. Guenard D, Guéritte-Vogelein F, Dubois J, Poitier P. Structure-activity relationships of taxol and taxotere analogues. Monogr Natl Cancer Inst. 15:1993;79-82.
3. R). Int J Radiation Oncol Biol Phys. 29:1994;559-564.
4. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of taxol as a radiosensitizer in human tumor cells. J Natl Cancer Inst. 86:1994;441-446.
5. Steren A, Sevin B-U, Perras J, et al. Taxol as a radiation sensitiser: a flow cytometric study. Gynecol Oncol. 50:1993;89-93.
6. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 22:1992;613-617.
7. Minarik L, Hall EJ. Taxol in combination with acute and low dose rate irradiation. Radiother Oncol. 32:1994;124-128.
8. Stromberg JS, Lee YJ, Armour EP, Martinez AA, Corry PM. Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer. 75:1995;2262-2268.
9. Wiernik PH, Schwartz EL, Strauman JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 47:1987;2486-2493.
10. Rowinsky EK. Clinical pharmacology of taxol. Monogr Natl Cancer Inst. 15:1993;25-37.
11. Beijnen JH, Huizing MT, ten Bokkel Huinink WW, et al. Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (taxol). Semin Oncol. 21:(Suppl 8):1994;53-62.
12. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol. 12:1994;2682-2686.
13. Akerley W, Choy H. Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Lung Cancer. 12:(Suppl 2):1995;S107-S115.
14. Trovò MG, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 24:1992;11-15.
15. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 326:1992;524-530.
16. Mirimanoff RO. Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): a review. Lung Cancer. 11:(Suppl 3):1994;S79-S99.
17. Murphy WK, Fonssella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst. 85:1993;384-394.
18. Ettinger DS. Taxol in the treatment of lung cancer. Monogr Natl Cancer Inst. 15:1993;177-179.
19. Comis RL, Friedland DM. New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Lung Cancer. 12:(Suppl 2):1995;S63-S99.
20. Pearson AE, Steel GG. Chemotherapy in combination with pelvic irradiation: a time dependence study in mice. Radiother Oncol. 2:1984;49-55.
21. Gibaldi M, Perrier D. 2nd edn. Non-Compartmental Analysis Based on Statistical Moment Theory in Pharmacokinetics. 1982;409-441 Marcel Dekker Inc. New York.
22. Grem JL, Tutsch KD, Simon KJ, et al. Taxol administered as a short IV infusion daily for 5 days. Cancer Treat Rep. 71:1987;1179-1180.
23. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 55:1995;3564-3568.
24. Milas L, Hunter NR, Kurdoglu B, et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol. 35:1995;297-303.
25. Milas L, Hunter NR, Mason KA, Kurdoglu B, Peters LJ. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 54:1994;3506-3510.
26. Donelli MG, D'Incalci M, Garattini S. Pharmacokinetic studies of anticancer drugs in tumour-bearing animals. Cancer Treat Rep. 68:1984;381-400.
27. Litterst C, LeRoy AF, Guarino AM. Disposition and distribution of platinum following parenteral administration of cis-diamminedichloroplatinum(II) to animals. Cancer Treat Rep. 63:1979;1485-1492.
28. 3H-vincristine by a mouse carcinoma during a course of fractionated radiotherapy. Br J Cancer. 60:1989;310-314.
29. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with Paclitaxel (Taxol) and Docetaxol (Taxotere) in HeLa and SQ20B cells. Cancer Res. 56:1996;1842-1850.
30. Begg AC, Van Der Kolk PJ, Dewit L, Bartelink H. Radiosensitisation by cisplatin of RIF1 tumour cells in vitro. Int J Radiat Biol. 50:1986;871-884.